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OBJECTIVES: To evaluate the level of compliance with antihypertensive medica-
tion among Greek hypertensive patients. Furthermore, to investigate the possible
association between non-compliance and patient profile as well as specific drug
categories. METHODS: A total of 2700 hypertensive patients participated and 2662
were analyzed in the study. The duration of the study was 9 months. Information
was collected on different antihypertensive drug categories along with epidemio-
logical data. Morisky scale was used in order to measure compliance. RESULTS: A
total of 57.5% of the responders were male (1530 patients) and 1130 were female.
Average age of responders was 63 years and average duration of hypertension was
8.6 years. 63.1% of the study population was found to be compliant with their
antihypertensive treatment (regardless of the type of antihypertensive treatment
the patient was receiving). From the Morisky scale, 36.2% of patients answered that
they sometimes forget to take their medication, 44.9% said that they were some-
times careless when it comes to taking their medicine, 26.9% that when they feel
better they forget to take their medicine and 18.4% of the study population an-
swered that when they feel worse, they relate this to their medication and discon-
tinue taking it. The factors found to influence compliance were the level of educa-
tion, the occupational status and the financial status of the patient as well as the
existence of conforming diseases such as duslipidemia and diabetes.
CONCLUSIONS: About four out of ten hypertensive patients fail to comply with
their prescribed treatment, increasing the possibility of poor control of their con-
dition. This may be an important obstacle in the assessment of the efficacy of any
pharmaceutical therapy and may influence the overall health levels of the patients,
since poorly controlled blood pressure may lead to the development of more seri-
ous conditions as Congestive Heart Failure and Coronary Heart Disease.
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OBJECTIVES:Antihypertensive agents have been shown to reduce the risk of major
cardiovascular events. However, there are no large effectiveness studies which
have assessed adherence to antihypertensive medications and major cardiovascu-
lar outcomes in high risk individuals who have recently suffered an ischemic
stroke. To evaluate the relationship between antihypertensive (AH) drug adher-
ence and cardiovascular (CV) outcomes among patients with a recent ischemic
stroke and to assess the validity of our approach. METHODS: A cohort of 14,227
patients with an ischemic stroke was assembled from individuals 65 years and
older who were treated with AH agents from 1999-2007 in the province of Quebec,
Canada. A nested case-control design was used to evaluate the occurrence of non-
fatal major CV outcomes, and mortality. Each case was matched to 15 controls by
age and cohort entry time. Medication possession ratio was used for AH agents
adherence level. Adjusted conditional logistic regression models were used to es-
timate the rate ratio of CV events. The validity of the approach was assessed by
evaluating the impact of adherence to CV protective and non-CV protective drugs.
RESULTS:Mean age was 75 years, 54% were male, 38% had coronary artery disease,
23% had diabetes, 47% dyslipidemia, and 14% atrial fibrillation or flutter. High
adherence to AH therapy decreased the risk of non-fatal vascular events compared
to lower level (Rate ratio: 0.77 (0.70-0.86). Male gender and CV disease were risk
factors for non-fatal vascular events. We observed a paradoxical relation between
adherence to several drugs and mortality risk. CONCLUSIONS: Adherence to AH
agents is associated with a risk reduction of non-fatal vascular events after a recent
ischemic stroke. Overestimation of an all-cause mortality reduction may be related
to frailty and comorbidity which may confound the apparent benefits of different
drugs.
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Vegter S, de Boer P, van Dijk KW, Visser ST, de Jong-van den Berg LT
University of Groningen, Groningen, The Netherlands
OBJECTIVES: A common adverse effect of angiotensin-converting enzyme inhibi-
tors (ACEi) is a persistent dry cough. Physicians and pharmacists who fail to recog-
nise dry cough to be ACEi related may prescribe cough suppressants (antitussives),
instead of recommended ACEi substitution. The aim of this study was to determine
the amount of antitussive treatment of ACEi-induced cough and the influence of
this on therapy compliance. METHODS: Prescription data from community phar-
macies between 2000 and 2012 were retrieved from the IADB.nl database in The
Netherlands. A prescription sequence symmetry analysis was used to determine
whether antitussive agents were prescribed more often following ACEi initiation
than the other way around. Therapy compliance was assessed using the proportion
of days covered (PDC) method; patients with a PDC 80% were considered
compliant. RESULTS: A total of 1898 starters of ACEi and antitussives within a
half-year time span were included. A significant excess of patients received anti-
tussives after ACEi initiation (1,269 versus 629), yielding a sequence ratio of 2.0 (CI:
1.8–2.2). The estimated proportion of patients with ACEi induced cough receiving
antitussives decreased over time: from 20.4% in 2000-2004 to 8.0% in 2008-2012.
Therapy compliance in patients receiving antitussives due to ACEi initiation was
52.4%, significantly lower than compliance in control patients, which was 75.2%
(P0.001). CONCLUSIONS: Many patients receive cough suppressants after ACEi
initiation. This suggests that ACEi induced cough is often either not recognized as
being ACEi related or is symptomatically treated. Such prescription behaviour is
ineffective and potentially harmful; it also decreases therapy compliance with ACE
inhibitors. The correct identification and management of this adverse drug effect is
an important aspect of pharmaceutical care.
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OBJECTIVES: To evaluate medication persistence in patients hypertensive chronic
who have different percentages of financial subsidy in a Program Benefit Manage-
ment (PBM). METHODS: We identified patients from 3 health care providers with
different percentages of subsidy to buy a medication using the same service in PBM
the first provider subsidizes 100%, the second subsidizes 90% (generic) and 70%
(brand) and third subsidizes 40%. We selected patients with age  40 years male
and female. The persistence analysis was made in the 12 months that followed
from the first acquisition within the using method MPR (Medication Possession
Ratio).The drugs was Antagonist of Angiotensin II Receptor (Losartan),Beta-Blocker
(Atenolol), Calcium Channel Blocker (amlodipine) and an inhibitor of angiotensin
converting enzyme (Enalapril). RESULTS: The persistence obtained with first pro-
vider (subsidizes 100%) Amlodipine n1266 and a persistence of 77.25%, n1016
Atenolol and a persistence of 44.39%, n680 and Enalapril a persistence of 90.00%
and Losartan n1157 and a persistence of 81.16% as an overall average of persis-
tence between the four drugs was 73.20%, the second provider (subsidizes 90% for
generic drugs and 70% for brand) obtained - Amlodipine n1948 and a persistence
of 78.49%, n2061 Atenolol and a persistence of 32.07%, n1265 Enalapril and
persistence 84.19% of Losartan and n2.166 and a persistence of 73.36% as an
overall average of persistence between four drugs 67.03% and the third provider
(subsidizes 40%), Amlodipine n1264 and a persistence of 9.34%, n1471 Atenolol
and a persistence of 9.11%, n941 Enalapril and a persistence of 36.88% and Losar-
tan n1917 and a persistence of 29.47% as a general average of persistence of the
four 21.20% drugs. CONCLUSIONS: The average persistence varies statistically sig-
nificantly with the percentage of subsidy the benefit influencing directly the per-
sistence of these populations, the greater the allowance / benefit was greater at the
rate of persistence between them.
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OBJECTIVES: To determine loss of health status, work productivity impairment,
and activity impairment associated with non-adherent cost-cutting in Russian hy-
pertension patients. METHODS: The study employed data from the 2011 Russia
National Health and Wellness Survey (NHWS; n10,039), a survey of demograph-
ics, health-related attitudes and behaviors, and health outcomes. Non-adherent
cost-cutting behaviors included taking less medication than prescribed, cutting
tablets in half, buying fewer tablets, not buying prescriptions recommended by the
physician, buying a less expensive alternative instead, or buying prescriptions less
often. Adherent behaviors included asking physician/ pharmacist for cheaper al-
ternatives, or using a discount card. Health status was assessed using the SF-12v2,
and work and activity impairment using the Work and Activity Impairment ques-
tionnaire (WPAI). Regression models quantified the burden associated with non-
adherent cost-cutting on health status and WPAI metrics, controlling for demo-
graphics, health history, insurance status, and comorbidities. RESULTS: Out of
1,712 diagnosed hypertension patients taking prescription medication for hyper-
tension, 37.5% reported using non-adherent cost-cutting behaviors, 28.2% reported
using adherent cost-cutting behaviors only, and 34.3% reported no cost-cutting
behaviors. After controlling for covariates, employed patients using non-adherent
strategies reported greater absenteeism (9.3% vs. 3.7%, p0.002), presenteeism
(29.2% vs. 21.8%, p0.001) and overall work productivity loss (33.8% vs. 24.3%,
p0.001) compared with employed patients who do not use those strategies.
Among all respondents, non-adherent cost-cutting was associated with lower ad-
justed health status (MCS: 42.0 vs. 44.4, p0.001, PCS: 40.3 vs. 41.3, p0.014) and
greater adjusted activity impairment (38.5% vs. 31.2%, p0.001). CONCLUSIONS:
Over a third of hypertension patients cut costs using strategies that interfere with
medication adherence. These patients suffer greater health-related impairments
in work and non-work activities and have lower health status. These patients
should be identified and guided to improve adherence to their prescription medi-
cations to facilitate better health outcomes.
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OBJECTIVES:Medication non-adherence and treatment satisfaction are significant
barriers to achieving treatment outcomes and associated with increased health
care costs among patients with hypertension. Using a novel patient registry, we
assessed factors associated with satisfaction and non-adherence to hypertension
medications.METHODS:We analyzed data from MediGuard.org, a free medication
monitoring service covering over 2.6 million members in the US, UK, France, Ger-
many, Spain, and Australia. As part of site operations, the service sends a quarterly
member survey to solicit feedback on their medications using the Treatment Sat-
isfaction Questionnaire for Medication (TSQM) and Medication Adherence Report
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Scale (MARS-5), valid and reliable instruments, amongst other questions. The
TSQM yields scores on effectiveness, side-effects, convenience, and global satis-
faction domains. Non-adherence was defined as a score of24 and adherence as a
score of 25 on MARS-5. Multivariate logistic regression and multivariable linear
regression were performed to identify patient characteristics (age, gender, number
of medications, severity, and hypertension drug class) and self-reported reasons
associated with non-adherence and treatment satisfaction.RESULTS:Between No-
vember 2011 and June 2012, 556 MediGuard.org members completed a survey re-
lated to an ACE or ARB: ACE358 (64.4%), ARB198 (35.6%). Patients had mean age
of 62.4 (SD:10.5) years (ACE61.7 years, ARB63.6 years) and 56.3% were female
(ACE58.1%, ARB53.1%). Overall, 51.5% reported medication non-adherence. The
mean TSQM score on effectiveness was 70.4(19.3), side-effects was 95.6(13.8), con-
venience was 84.6(14.0), and global satisfaction was 67.4(19.2). Forgetting, don’t like
to take pills/give injection, and gender were significantly associated with non-
adherence (p0.05). Age, gender, and don’t like to take pills/give injection were
significantly associated with effectiveness, side-effects, and convenience domain
(p0.05), respectively. Age and don’t like to take pills/give injection were signifi-
cantly associated with global satisfaction (p0.05). CONCLUSIONS: In addition to
patient characteristics, patient preferences are important to potentially improve
adherence and satisfaction to hypertension medications.
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OBJECTIVES: To identify multi-attribute utility (MAU) values associated with ve-
nous thromboembolism (VTE) events and to select values for use in economic
models. METHODS: A systematic review of the literature was conducted including
database searches and hand-searching of relevant studies. The database search
included utility studies or RCTs reporting utility scores. The disease area and pop-
ulation were restricted to VTE and adults, respectively. All identified economic
evaluations were hand-searched in order to explore utilities from different eco-
nomic evaluations. Utility sources from three previously developed economic
models for rivaroxaban were also explored. Studies reporting the 8 SF-36 compo-
nents were transformed to EQ-5D using a mapping model outlined by Ara and
Brazier (2008). RESULTS: The database search identified 576 citations, of which 20
studies were included in the review. The hand-search identified 1 study. Two ad-
ditional studies were identified from the economic models, giving a total of 23
studies. Of the 23 studies, 2 studies reported MAUs; 7 studies used direct preference
based measures such as the time trade off technique and the remaining 14 studies
used non-preference based measures such as SF-36. Of the 14 non-preference
based measures, 5 reported mean SF-36 scores for all components and were trans-
formed to EQ-5D. A total of 50 utility values were extracted from the studies. The
selection process identified the following utility scores: 0.62 for DVT, 0.63 for PE and
0.7855 for VTE long-term complications. CONCLUSIONS: There was a large varia-
tion in the extracted utilities (0.04-0.992). Long-term disutility has greater influence
than acute. Cost-utility analyses should model the relationship between acute VTE
events and long-term disutility to capture all health related quality of life impair-
ment.
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OBJECTIVES: To solve problems with recall and aggregation bias in the measure-
ment of utilities it was suggested to determine experienced health moment-by-
moment using the Experience Sampling Method (ESM). This study describes a first
test of feasibility and validity. METHODS: In total 160 persons were included (4
groups with N40; tinnitus, anxiety/depression, atherosclerosis, general public).
ESM data (including health, mood and contextual factors) were collected electron-
ically for six days using a beep questionnaire (10 random times a day) and an
end-of-day questionnaire. In the beep questionnaire a beep-VAS, anchored as the
EQ-5D VAS, was included. In the end-of-day questionnaire the EQ-5D items were
also included, and used to calculate EoD-Utility. Directly before and after the ESM-
period the EQ-5D and Hospital Anxiety and Depression Scale (HADS) were admin-
istered, and used to calculate Before and After utility and VAS scores. Feasibility,
subjective data and convergent validity of ESM, and differences between scores
were analyzed. The relation between beep-VAS, health and mood at beep level
were determined with multilevel analyses. RESULTS: All participants completed
the ESM period and before and after questionnaires. Correlation between beep data
(mean per day) and EoD reports are high for well-being (r.836) and feeling sick
(r.737). Correlations between beep anxiety/depression and the HADS scores are
high (r.627;r.565). In the tinnitus and general public groups, the aggregated
beep-VAS scores (0.65;0.82) are lower than the Before-VAS scores (0.68;0.89) and
After-VAS scores (0.71;0.91). The aggregated EoD-Utility scores (0.80;0.95) are not
different from the After-Utility scores (0.79;0.96). However, in the tinnitus group the
EoD-utility score (0.80) is higher than the Before-Utility score (0.74). Results of the
other groups, and multilevel analyses will be presented at the conference.
CONCLUSIONS: Feasibility and validity of ESM were satisfactory. Health state
scores obtained moment-by-moment using ESM differ from the scores obtained by
using the traditional approach.
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OBJECTIVES: To develop a conceptual model that captures the types of burden and
associated impacts experienced by chronic heart failure (CHF) caregivers.
METHODS: Qualitative interviews were conducted with 24 adult CHF caregivers
from 2 US cities. The 60-minute interviews involved exploratory questions about
the CHF caregiving experience and its impact on caregivers’ quality of life. Data
were analyzed based on Grounded Theory methods. RESULTS: Caregivers were
5311 years, 67% female, 33% non-Caucasian, 37% children of the CHF patients,
17% patient’s spouse and 63% resided with the CHF patient. Qualitative analysis
indicated 4 domains of caregiver burden: (1) physical burdens included tiredness,
health deterioration, physical effort, lack of sleep; (2) emotional/psychological burdens
included feeling overly depended on, worried, guilty, mentally drained, stressed, a
loss of independence, sadness, and feeling overwhelmed; (3) social burdens included
spending less time with family and friends and the decline in the quality of those
relationships, as well as impact on sexual relationships, (4) impact on caregivers’
lifestyles included a lack of time for themselves and non-caregiving tasks, changing
plans, having to stay near to the patient, and the impact at work and on the care-
giver-patient relationship. Many external factors were also described by the care-
givers as impacting the level of burden, such as the patient’s health status or mood,
the volume of the caregivers’ tasks and the level of support from others. This data
has been captured in a conceptual model of CHF caregiver burden. CONCLUSIONS:
The burdens placed on CHF caregivers are multifaceted. The understanding of
these burdens within a valid conceptual model will allow the development of in-
struments to measure the level of CHF caregiver burden. Further research is re-
quired to understand and quantify the link between CHF patients’ symptomology
and the level of burden that this places on caregivers.
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OBJECTIVES: To assess the impact of symptoms in patients with Atrial Fibrilation
(AF) through AF-QoL, a specific questionnaire to measure Health Related Quality of
Life (HRQoL). METHODS: Observational cross-sectional study in cardiologist set-
ting. Patients included were18 years old with paroxystic AF (AFPar) or persistent
AF (AFPer). Main clinical variables: type of AF, NYHA functional stage, symptoms
frequency and duration and CHADS2 index. AF-QoL has 18 items and 3 domains:
psychological, physical and sexual activity, and scores standardized between 0
(worst HRQoL) and 100 (best HRQoL). RESULTS: A total of 824 patients were in-
cluded: 513 (62.3%) with AFPar and 311 (37.7%) with AFPer. 56.1% were male and
mean (SD) age was 68.2 (11.3) years. Patients with AFPar were younger than AFPer
(p0.001). 82.8% and 26.1% of patients with AFPar had palpitations and dyspnea vs.
62.4% and 44.7% of AFPer (p0.001). AFPar was associated to higher thromboem-
bolism risk by CHADS2 (p0.001). Global mean (SD) score for AF-QoL was similar
between both types of AF: 51.23 (23.76) in AFPar and 46.68 (24.48) in AFPer, but
differences were observed in physical domain having AFPar a higher mean score
that AFPer (p0.003). Multivariate analysis showed that being male, having pres-
ence of mild or no symptoms, practicing exercise, having NYHA stage I and II and
not having emergency visits was related with higher score of HRQoL (R20.32;
p0.0001). CONCLUSIONS: AF symptoms have a high impact in HRQoL of patient.
Therapies able to reduce severity of symptoms and number of emergency visits
will have a positive impact on HRQoL in patients with AF.
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PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) AND THE SF-36
IN PATIENTS WITH PULMONARY HYPERTENSION
Twiss J1, Ganderton L2, Jenkins S3, Ben-L’amri M1, Gain K4, Fowler R3, Gabbay E3,
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OBJECTIVES: The Cambridge Pulmonary Hypertension Outcome Review (CAM-
PHOR) and the Medical Outcomes Study Short Form 36 (SF-36) are widely used to
assess outcome in pulmonary hypertension (PH) patients. The CAMPHOR is a PH-
specific measure consisting of three scales; symptoms, activity limitations and
needs-based QoL. The SF-36 is a generic health status questionnaire consisting of
36 items and eight domains. The aim of this study was to compare the psychomet-
ric properties of these two measures in a population with PH. METHODS: Partici-
pants were recruited from six specialist PH centres in Australia and New Zealand.
They completed the CAMPHOR and SF-36 at two time points, two weeks apart. The
questionnaires were assessed for distributional properties (% scoring minimum
and % scoring maximum), internal consistency (Cronbach’s alpha), test-retest re-
liability (minimum required correlation coefficient  0.85) and construct validity
(CAMPHOR scores by WHO functional classification). RESULTS: The sample com-
prised 65 participants (mean (SD): age 57.2 (14.5) years; male n (%): 14 (21.5)). Most
of the participants were in WHO functional class II (27.7%) or III (61.5%). A high
proportion of participants recorded the maximum score for the SF-36 social func-
tioning (21.3%) and role emotional (25.0%) domains, signifying insensitivity. Test-
retest reliability was below the required level for six of the eight SF-36 domains,
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